Last updated on November 2019

Safety and Efficacy of Humira (Adalimumab) for Hidradenitis Suppurativa (HS) Peri-Surgically (SHARPS Study)


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Hidradenitis Suppurativa
  • Age: Between 18 - 65 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Participant must have skin lesions that are diagnostic of Hidradenitis Suppurativa (HS) for at least 1 year (365 days) prior to the Baseline visit
  • Participant must have at least 3 distinct anatomical regions involved with inflammatory ( also termed 'active') HS lesions; plus
  • either one axilla or one inguinal region (limited to the inguino-crural fold and adjacent areas) that requires excisional surgery, and
  • with at least one of the other affected HS regions (e.g., contralateral inguinal region, buttocks, inframammary region) rated as Hurley Stage II or III
  • Participant must have a total abscess and inflammatory nodule (AN) count of greater than or equal to 3 at the Baseline visit within the HS non-surgical sites
  • The HS surgical site must contain at least one active HS lesion
  • The HS surgical site must require excisional surgery and is large enough to require healing by secondary intention as assessed by the designated surgeon

Exclusion Criteria:

  • Has a draining fistula count of greater than 20 at the Baseline visit
  • Requires surgery at any anatomical site other than an unilateral axilla or inguinal region site
  • Requires surgical management prior to Week 13
  • Requires, based on the designated surgeon's assessment, excisional surgery with primary closure as the method of closure being most beneficial for the participant

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.